Response to Letter Regarding Article, “Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults”

We thank Drs Zou and Zheng for their comments.1 We agree that future research will need to establish whether measuring fibroblast growth factor 23 may be useful for reducing stroke rates, either as a biomarker for improving cardioembolic stroke risk stratification or potentially as a target of therapy.

Disclosures

None.

Orlando M. Gutiérrez, MD, MMSc
Department of Medicine
University of Alabama at Birmingham

Response to Letter Regarding Article, "Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults"
Orlando M. Gutiérrez

Stroke. 2015;46:e124; originally published online March 17, 2015; doi: 10.1161/STROKEAHA.115.008910

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/46/5/e124

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/